@prefix this: <
http://www.tkuhn.ch/bel2nanopub/RAgwbL0x6g5gnqtm1k61WKu3fOF83EMlh6-YrMtYPJG0Y
> .
@prefix sub: <
http://www.tkuhn.ch/bel2nanopub/RAgwbL0x6g5gnqtm1k61WKu3fOF83EMlh6-YrMtYPJG0Y#
> .
@prefix beldoc: <
http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel
> .
@prefix rdfs: <
http://www.w3.org/2000/01/rdf-schema#
> .
@prefix rdf: <
http://www.w3.org/1999/02/22-rdf-syntax-ns#
> .
@prefix xsd: <
http://www.w3.org/2001/XMLSchema#
> .
@prefix dct: <
http://purl.org/dc/terms/
> .
@prefix dce: <
http://purl.org/dc/elements/1.1/
> .
@prefix pav: <
http://purl.org/pav/
> .
@prefix np: <
http://www.nanopub.org/nschema#
> .
@prefix belv: <
http://www.selventa.com/vocabulary/
> .
@prefix prov: <
http://www.w3.org/ns/prov#
> .
@prefix chebi: <
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=
> .
@prefix RNA: <
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_33697
> .
@prefix mgi: <
http://www.informatics.jax.org/marker/MGI:
> .
@prefix geneProductOf: <
http://purl.obolibrary.org/obo/RO_0002204
> .
@prefix do: <
http://disease-ontology.org/term/DOID:
> .
@prefix occursIn: <
http://purl.obolibrary.org/obo/BFO_0000066
> .
@prefix species: <
http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=
> .
@prefix pubmed: <
http://www.ncbi.nlm.nih.gov/pubmed/
> .
@prefix orcid: <
http://orcid.org/
> .
sub:Head
{
this:
np:hasAssertion
sub:assertion
;
np:hasProvenance
sub:provenance
;
np:hasPublicationInfo
sub:pubinfo
;
a
np:Nanopublication
.
}
sub:assertion
{
sub:_1
geneProductOf:
mgi:88311
;
a
RNA:
.
sub:_2
occursIn:
do:1324
,
species:10090
;
rdf:object
sub:_1
;
rdf:predicate
belv:decreases
;
rdf:subject
chebi:50859
;
a
rdf:Statement
.
sub:assertion
rdfs:label
"a(CHEBI:bexarotene) -| r(MGI:Ccnb2)" .
}
sub:provenance
{
beldoc:
dce:description
"Approximately 61,000 statements." ;
dce:rights
"Copyright (c) 2011-2012, Selventa. All rights reserved." ;
dce:title
"BEL Framework Large Corpus Document" ;
pav:authoredBy
sub:_4
;
pav:version
"20131211" .
sub:_3
prov:value
"The effect of budesonide on the mRNA expression of caspase 3, cyclin B2, cyclin E1, iNOS and survivin was determined, because targretin, another effective chemopreventive agent, was reported to decrease the expression of the 5 genes in mouse lung tumors.[11]" ;
prov:wasQuotedFrom
pubmed:17163412
.
sub:_4
rdfs:label
"Selventa" .
sub:assertion
prov:hadPrimarySource
pubmed:17163412
;
prov:wasDerivedFrom
beldoc:
,
sub:_3
.
}
sub:pubinfo
{
this:
dct:created
"2014-07-03T14:33:07.579+02:00"^^
xsd:dateTime
;
pav:createdBy
orcid:0000-0001-6818-334X
,
orcid:0000-0002-1267-0234
.
}